September 20 24.

Amgen to provide its four Phase 3 clinical trial results Amgen today announced it’ll present detailed data from 4 Phase 3 studies as well as other data in the ECCO 15 – ESMO 34 European Multidisciplinary Congress, September 20 – 24, 2009 in Berlin, Germany malegra fxt read more . Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa for the treatment of bone metastases in patients with advanced breast tumor and the treatment of bone metastases in advanced malignancy sufferers with solid tumors or multiple myeloma . Related StoriesMD Anderson research reveals why chemotherapy medications not effective for most pancreatic cancer patientsStudy displays rare HER2 missense mutations usually do not spread breast cancer on their ownNew RNA test of blood platelets may be used to detect area of cancerDetailed data will also be presented from two Stage 3 studies evaluating Vectibix in combination with chemotherapy for the first-line and second-series treatment of metastatic colorectal cancer tumor .

malegra canada

Amgen in addition has agreed to reacquire privileges in Brazil to its items which were previously granted to Mantecorp . Together, these transactions provides Amgen a significant existence in Brazil and immediate, direct access to one of the fastest developing pharmaceutical marketplaces in the world. Bergamo is a respected supplier of medications to the hospital sector in Brazil with features in oncology medicines and has manufacturing facilities in Sao Paulo condition. Today Under terms of the purchase announced, Amgen gained full possession of Bergamo by purchasing it for approximately US $215 million. Amgen’s strategic goal is to make our innovative medicines open to patients in major markets all over the world, said Kevin Sharer, Amgen’s chairman and chief executive officer.